Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
ConclusionCamrelizumab plus sorafenib showed favorable efficacy and manageable toxicity for patients with advanced HCC. However, more prospective randomized trials are necessary to further verify the potential clinical benefits of this combination therapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Immunotherapy | Liver Cancer | Statistics | Study | Thrombocytopenia | Toxicology